These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26325242)

  • 1. Ebola virus vaccine: benefit and risks of adenovirus-based vectors.
    Mennechet FJ; Tran TT; Eichholz K; van de Perre P; Kremer EJ
    Expert Rev Vaccines; 2015; 14(11):1471-8. PubMed ID: 26325242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ebola vaccines - Where are we?
    Watle SV; Norheim G; Røttingen JA
    Hum Vaccin Immunother; 2016 Oct; 12(10):2700-2703. PubMed ID: 27548643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.
    Suder E; Furuyama W; Feldmann H; Marzi A; de Wit E
    Hum Vaccin Immunother; 2018; 14(9):2107-2113. PubMed ID: 29757706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.
    Zhou Y; Sullivan NJ
    Curr Opin Immunol; 2015 Aug; 35():131-6. PubMed ID: 26247875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vaccine against Ebola: Problems and opportunities.
    Rezza G
    Hum Vaccin Immunother; 2015; 11(5):1258-60. PubMed ID: 25901415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of vaccines for Ebola virus disease.
    Ohimain EI
    Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.
    Choi JH; Schafer SC; Freiberg AN; Croyle MA
    Mol Pharm; 2015 Aug; 12(8):2697-711. PubMed ID: 25549696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-vectored Ebola vaccines.
    Gilbert SC
    Expert Rev Vaccines; 2015; 14(10):1347-57. PubMed ID: 26289977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials for Ebola vaccines staged in Africa, North America and Europe.
    Hum Vaccin Immunother; 2014; 10(12):3427-8. PubMed ID: 26052585
    [No Abstract]   [Full Text] [Related]  

  • 10. Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts.
    Sheets RL; Stein J; Bailer RT; Koup RA; Andrews C; Nason M; He B; Koo E; Trotter H; Duffy C; Manetz TS; Gomez P
    J Immunotoxicol; 2008 Jul; 5(3):315-35. PubMed ID: 18830892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From bench to almost bedside: the long road to a licensed Ebola virus vaccine.
    Wong G; Mendoza EJ; Plummer FA; Gao GF; Kobinger GP; Qiu X
    Expert Opin Biol Ther; 2018 Feb; 18(2):159-173. PubMed ID: 29148858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebola: Lessons on Vaccine Development.
    Feldmann H; Feldmann F; Marzi A
    Annu Rev Microbiol; 2018 Sep; 72():423-446. PubMed ID: 30200851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine.
    Grobusch MP; Goorhuis A
    Lancet; 2017 Feb; 389(10069):578-580. PubMed ID: 28017405
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.
    Tully CM; Lambe T; Gilbert SC; Hill AV
    Lancet Infect Dis; 2015 Mar; 15(3):356-9. PubMed ID: 25595637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Overview of the Ebola vaccines in pre-clinical and clinical development].
    Buchy P
    Bull Soc Pathol Exot; 2016 Oct; 109(4):256-261. PubMed ID: 27646961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.
    Higgs ES; Dubey SA; Coller BAG; Simon JK; Bollinger L; Sorenson RA; Wilson B; Nason MC; Hensley LE
    Curr Top Microbiol Immunol; 2017; 411():229-261. PubMed ID: 28918539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses.
    Seki S; Matano T
    Expert Rev Vaccines; 2016; 15(1):119-27. PubMed ID: 26512881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
    Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
    J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.